Fig. 3From: Long-term effectiveness and safety of infliximab, golimumab and golimumab-IV in rheumatoid arthritis patients from a Canadian prospective observational registryEffect of treatment with IFX, GLM and GLM-IV on disease parameters over time. Observed data with X-axis cut at 120 months for clarity (goes up to 168 months for IFX; n = 4). P value vs baselineBack to article page